Cidara Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Cidara Therapeutics, Inc. Overview

Cidara Therapeutics operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis. Most significantly, Merck agreed to acquire Cidara for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion following FDA Breakthrough Therapy designation.

Strategic Profile

The company's proprietary Cloudbreak platform enables development of novel drug-Fc conjugates, with CD388, a long-acting antiviral for influenza prevention, earning Breakthrough Therapy designation from the FDA in October 2025. CD388 demonstrated up to 76.1% prevention efficacy in Phase 2b trials. The $9.2 billion acquisition by Merck validates the platform's potential as a game-changing antiviral technology with applications beyond influenza.

Competitive Landscape

CD388 is a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza. The antiviral space includes competitors like Tamiflu (oseltamivir), but CD388's long-acting, strain-agnostic mechanism represents a potentially differentiated approach. The Cloudbreak platform's broader drug-Fc conjugate technology may also enable oncology and infectious disease applications, competing with traditional biopharmaceutical development approaches.

Industry Context

Cidara Therapeutics, Inc. operates in Infectious Disease Drugs.

Key facts

Founded: 2012 · Headquarters: San Diego, California, US · Employees: ~70 (August 2024) · Revenue: ~$0 (pre-revenue clinical-stage company as of Q2 2025) · Market cap: ~$9.2B (acquisition value, November 2025)